SCHEMBL4913399

SCHEMBL4913399

CCOC(=O)c1ccc2c(c1)ncn2CCC(C)(C)N

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
F10 P00742 2/20 0.46
HPGD P15428 1/20 0.45
SIRT2 Q8IXJ6 5/20 0.44
SIRT1 Q96EB6 4/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
F2 P00734 1/20 0.43
PRSS1 P07477 1/20 0.43
RECQL P46063 1/20 0.43
MAPK10 P53779 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 2/20 0.42
NLRP3 Q96P20 1/20 0.42
HDAC1 Q13547 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PDE2A O00408 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4916141 0.92 NPC1 (0.48) NPC1RAB9AF10SIRT2SIRT1
SCHEMBL14800208 0.86 HPGD (0.53) NPC1RAB9AF10HPGDSIRT2
SCHEMBL9126131 0.83 RAB9A (0.57) NPC1RAB9AF10HPGDSIRT2
SCHEMBL9461934 0.83 HPGD (0.51) NPC1RAB9AF10HPGDSIRT2
SCHEMBL14800316 0.82 MEN1 (0.54) NPC1RAB9AF10HPGDMEN1
SCHEMBL9038215 0.82 HPGD (0.53) NPC1RAB9AF10HPGDSIRT2
SCHEMBL4907499 0.82 NPC1 (0.45) NPC1RAB9AF10HPGDSIRT2
SCHEMBL4640769 0.82 CA2 (0.44) NPC1RAB9AF10HPGDMEN1
SCHEMBL4889652 0.82 CNR2 (0.41) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL6806002 0.81 HDAC1 (0.52) NPC1RAB9AF10HPGDSIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080103138-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-01 US disclosed
US-20080103138-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-01 US disclosed
US-20070112033-A1 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-17 US disclosed
US-20070112033-A1 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103138-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions ADRB1, ADRB3, ADRB2 NPC1 1596/4885RAB9A 1706/4885F10 2832/4885
US-20070112033-A1 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance ADRB3, ADRB1, ADRA1B NPC1 1873/4885RAB9A 1943/4885F10 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.